Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients

World J Gastroenterol. 2008 Apr 28;14(16):2522-8. doi: 10.3748/wjg.14.2522.

Abstract

Aim: To evaluate the epidemiological, clinical, laboratory and histological variables capable of predicting the progression of hepatic structural disturbances in chronic hepatitis C patients during the time interval between two liver biopsies.

Methods: Clinical charts of 112 chronic hepatitis C patients were retrospectively analyzed, whereas liver biopsies were revised. Immunohistochemical detection of interferon receptor was based on the Envision-Peroxidase System.

Results: In the multivariate analysis, the variables in the age at first biopsy, ALT levels, presence of lymphoid aggregates and siderosis were the determinants of the best model for predicting the severity of the disease. The direct progression rate of hepatic structural lesions was significantly higher in untreated patients, intermediate in treated non-responders and lower in treated responders to antiviral therapy (non-treated vs responders, 0.22 +/- 0.50 vs -0.15 +/- 0.46, P = 0.0053). Immuno-expression of interferon receptor is not a relevant factor.

Conclusion: The best predictors of the progression of fibrosis are age at the first liver biopsy, extent of ALT elevation, inflammation at liver histology and hepatic siderosis. Antiviral treatment is effective in preventing the progression of liver structural lesions in chronic hepatitis C patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biopsy
  • Disease Progression
  • Female
  • Hepatitis C, Chronic / etiology
  • Hepatitis C, Chronic / pathology*
  • Hepatitis C, Chronic / physiopathology
  • Humans
  • Immunohistochemistry
  • Liver Cirrhosis / pathology
  • Liver Cirrhosis / physiopathology
  • Liver Cirrhosis / virology
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prognosis
  • Receptors, Interferon / metabolism
  • Regression Analysis

Substances

  • Receptors, Interferon